# A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

> **NCT02670213** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 8 (estimated)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FXIII Deficiency

## Interventions

- **DRUG:** recombinant factor XIII

## Key facts

- **NCT ID:** NCT02670213
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-16
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670213, "A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02670213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*